Literature DB >> 10808199

Hematopoietic stem cell transplants after reduced intensity conditioning regimen (RI-HSCT): report of a workshop of the European group for Blood and Marrow Transplantation (EBMT).

A Bacigalupo1.   

Abstract

Allogeneic minitransplants are being increasingly used for the treatment of hematologic malignancies. Eligibility criteria usually include age over 60 years and/or major clinical problems concomitant with the hematologic disorder. This report summarizes a workshop which was held in 1999 under the auspices of EBMT: the issues discussed included stem cell sources and mobilization techniques, stem cell engraftment, accessory cells, mixed chimerism, graft-versus-tumor effect and ongoing clinical trials. There are many questions which still need to be answered, but this area of transplantation seems very promising and will certainly develop in the coming years.

Entities:  

Mesh:

Year:  2000        PMID: 10808199     DOI: 10.1038/sj.bmt.1702385

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  10 in total

1.  Refinement of treatment strategies in ex vivo T-cell-depleted haploidentical SCT for pediatric patients.

Authors:  H J Im; K N Koh; J K Suh; S W Lee; E S Choi; S Jang; S W Kwon; C-J Park; J J Seo
Journal:  Bone Marrow Transplant       Date:  2014-10-13       Impact factor: 5.483

2.  Paediatric reduced intensity conditioning: analysis of centre strategies on regimens and definitions by the EBMT Paediatric Diseases and Complications and Quality of Life WP.

Authors:  A Lawitschka; M Faraci; I Yaniv; P Veys; P Bader; J Wachowiak; G Socie; M D Aljurf; M Arat; J J Boelens; R Duarte; A Tichelli; C Peters
Journal:  Bone Marrow Transplant       Date:  2015-01-26       Impact factor: 5.483

3.  Haploidentical HCT using an αβ T-cell-depleted graft with targeted αβ(+) cells by add-back after a reduced intensity preparative regimen containing low-dose TBI.

Authors:  H J Im; K N Koh; J K Suh; S W Lee; E S Choi; S Jang; S W Kwon; C-J Park; J J Seo
Journal:  Bone Marrow Transplant       Date:  2016-05-09       Impact factor: 5.483

4.  Dose intensity for conditioning in allogeneic hematopoietic cell transplantation: can we recommend "when and for whom" in 2021?

Authors:  Nico Gagelmann; Nicolaus Kröger
Journal:  Haematologica       Date:  2021-07-01       Impact factor: 9.941

5.  Myeloablative busulfan/cytoxan conditioning versus reduced-intensity fludarabine/melphalan conditioning for allogeneic hematopoietic stem cell transplant in patients with acute myelogenous leukemia.

Authors:  Vishal Dhere; Scott Edelman; Edmund K Waller; Amelia Langston; Michael Graiser; Erin C Connolly; Jeffrey M Switchenko; Natia Esiashvili; Mohammad K Khan
Journal:  Leuk Lymphoma       Date:  2017-08-07

6.  Reduced-intensity and myeloablative conditioning allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and myelodysplastic syndrome: a meta-analysis and systematic review.

Authors:  Wen Zeng; Lifang Huang; Fankai Meng; Zeming Liu; Jianfeng Zhou; Hanying Sun
Journal:  Int J Clin Exp Med       Date:  2014-11-15

7.  Clinical Characteristics and Outcome Analysis for HLA Loss Patients Following Partially Mismatched Related Donor Transplantation Using HLA Chimerism for Loss of Heterozygosity Analysis by Next-Generation Sequencing.

Authors:  Andi Wang; Wenjun Li; Fei Zhao; Zhongzheng Zheng; Ting Yang; Sanbin Wang; Jinsong Yan; Jianpin Lan; Shengjin Fan; Mingfeng Zhao; Jianpin Shen; Xin Li; Tonghua Yang; Quanyi Lu; Ying Lu; Hai Bai; Haiyan Zhang; Dali Cai; Ling Wang; Zhiyang Yuan; Erlie Jiang; Fang Zhou; Xianmin Song
Journal:  Cell Transplant       Date:  2022 Jan-Dec       Impact factor: 4.139

Review 8.  Therapeutic applications of non-myeloablative hematopoietic stem cell transplantation in malignant disease.

Authors:  William J Hogan; Rainer Storb
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

9.  Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research.

Authors:  Sergio Giralt; Karen Ballen; Douglas Rizzo; Andreas Bacigalupo; Mary Horowitz; Marcelo Pasquini; Brenda Sandmaier
Journal:  Biol Blood Marrow Transplant       Date:  2009-03       Impact factor: 5.742

10.  Frequency and Risk Factors of Cyclosporine-Induced Neurotoxicity in Allogeneic Stem Cell Transplant Recipients.

Authors:  Asma Danish; Sarah I Mughal; Uzma Zaidi; Shabnam Dildar; Shafaq Samad; Aisha Jamal; Zainab Sharif; Tahir Shamsi
Journal:  Cureus       Date:  2021-11-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.